Loading...
Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines
Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in...
Saved in:
| Published in: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Impact Journals LLC
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205545/ https://ncbi.nlm.nih.gov/pubmed/30416685 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|